The Gut‐Liver Axis in Metabolic Dysfunction‐Associated Steatotic Liver Disease: From Mechanistic Insights to Precision Therapeutics
The FASEB Journal · 31.03.2026 · 40 (6)
DOI: 10.1096/fj.202503607rr ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 13.03.2026. Verfasst von Shaoliang Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary, Pancreas and Spleen Surgery, the People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Scien…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Precision Medicine, Liver, Fatty Liver. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Guangxi Natural Science Fundation, Guangxi Youth Science Fun Project, Research Foudation for Advanced Talents of The people's and Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Science.
Abstract (Originalsprache)
Metabolic dysfunction‐associated steatotic liver disease (MASLD) has become the most prevalent chronic liver condition globally, shifting the diagnostic paradigm toward an affirmative, metabolism‐focused framework. The gut‐liver axis is a central pathophysiological pathway. This review aims to synthesize revolutionary advances from 2023 to 2025 in understanding and treating MASLD by focusing on the gut microbiome's role. This comprehensive review analyzes cutting‐edge research published between 2023 and 2025. We examined evidence from landmark clinical trials, developments in next‐generation probiotics, the integration of artificial intelligence (AI) with multiomics for diagnostics, and studies clarifying the interplay between host genetics and the microbiome in MASLD pathogenesis. Causal links between gut dysbiosis and MASLD pathology are now firmly established. Fecal microbiota transplantation (FMT) effectively prevents hepatic encephalopathy recurrence, and next‐generation probiotics like Akkermansia muciniphila have entered MASLD‐specific trials. AI‐driven diagnostic tools have achieved regulatory qualification from the European Medicines Agency. Furthermore, host genetics, particularly PNPLA3 variants, are shown to not only predispose to MASLD but also shape specific microbial communities that functionally contribute to disease progression. The field is rapidly advancing from correlative observations to causal evidence, enabling the development of microbiome‐based biomarkers and personalized therapies. The future of MASLD management lies in precision strategies, such as bacteriophage therapy and functionally defined probiotics, which integrate metabolic, microbial, and genetic factors into individualized care, heralding a new therapeutic era.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatobiliary, Pancreas and Spleen Surgery, the People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, China.
- Department of Nephrology, the People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, China.
- Department of Anesthesiology, the People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, China.
- Institute of Oncology, the People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, China.
ORCID-Profile: Honglin Luo
Förderung
- Guangxi Natural Science Fundation
- Guangxi Youth Science Fun Project
- Research Foudation for Advanced Talents of The people's and Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Science
Zitieren
APA
Zhu, S., Zou, M., Wu, Q., Zou, Y., Tan, T., Huang, Z., Gong, Z., Luo, H., & Dong, X. (2026). The Gut‐Liver Axis in Metabolic Dysfunction‐Associated Steatotic Liver Disease: From Mechanistic Insights to Precision Therapeutics. The FASEB Journal, 40(6). https://doi.org/10.1096/fj.202503607rr
Vancouver
Zhu S, Zou M, Wu Q, Zou Y, Tan T, Huang Z, et al. The Gut‐Liver Axis in Metabolic Dysfunction‐Associated Steatotic Liver Disease: From Mechanistic Insights to Precision Therapeutics. The FASEB Journal. 2026;40(6). doi:10.1096/fj.202503607rr
BibTeX
@article{Zhu2026,
author = {Zhu, Shaoliang and Zou, Mengjie and Wu, Qijun and Zou, Yan and Tan, Tingting and Huang, Zhangnan and Gong, Zheng and Luo, Honglin and Dong, Xiaofeng},
title = {The Gut‐Liver Axis in Metabolic Dysfunction‐Associated Steatotic Liver Disease: From Mechanistic Insights to Precision Therapeutics},
journal = {The FASEB Journal},
year = {2026},
volume = {40},
number = {6},
doi = {10.1096/fj.202503607rr}
}
EUVIMED